AstraZeneca COVID-19 vaccine safety data - People affected by cancer and transplant recipients AstraZeneca COVID-19 vaccine Main navigation COVID-19 vaccines Moderna XBB.1.5 COVID-19 vaccine Pfizer XBB.1.5 COVID-19 vaccine Pfizer bivalent BA.4/5 COVID-19 vaccine Moderna bivalent COVID-19 vaccine Pfizer bivalent BA.1 COVID-19 vaccine Pfizer COVID-19 vaccine adult formulation Pfizer COVID-19 vaccine paediatric formulation (5–11 years) Moderna COVID-19 vaccine Novavax COVID-19 vaccine AstraZeneca COVID-19 vaccine All participants Aboriginal and Torres Strait Islander participants Adolescent participants People affected by cancer and transplant recipients Influenza vaccines National Immunisation Program schedule vaccines Mpox (monkeypox) vaccine Shingrix® AusVaxSafety has been actively monitoring the short-term adverse event profile of COVID-19 vaccines used in Australia through post-vaccination safety surveys that allow vaccine recipients to report any adverse events they may have experienced at different intervals following vaccination. These surveys also allow individuals to report pre-existing medical conditions, allowing AusVaxSafety to capture COVID-19 vaccine safety data, specific to Australia, for people affected by cancer and transplant recipients. AusVaxSafety captures COVID-19 vaccine safety data for the following cancer and transplant recipient population groups: Cancer (not including blood or bone marrow cancer) diagnosed in the last 12 months Blood cancer (e.g. leukaemia, lymphoma or myelodysplastic syndrome) diagnosed within the last 5 years Organ transplant recipient on immune suppressive therapy or bone marrow transplant recipient in the last 2 years AusVaxSafety has analysed the data collected from people who reported the above pre-existing conditions and have created infographics outlining the short-term adverse event profile for each group, including a comparison to the general population. These infographics provide individuals affected by cancer and transplant recipients with real-world information on what to expect following AstraZeneca COVID-19 vaccination and can be used when planning for COVID-19 vaccination. AusVaxSafety has reaffirmed the safety of these vaccines. Data on this page will no longer be updated. Find out more here. Cancer (not including blood or bone marrow cancer) The profile of reported events from AusVaxSafety surveillance of the AstraZeneca COVID-19 vaccine is similar to that reported in clinical trials and from post-marketing surveillance overseas. There have been no reports of thrombosis thrombocytopenia syndrome (TTS) following COVID-19 vaccination reported to AusVaxSafety. For more information on all vaccine safety monitoring in Australia and on TTS, see weekly TGA safety updates. AusVaxSafety's active vaccine safety surveillance system complements the TGA's enhanced safety surveillance activities. Find out more about how the TGA monitors the safety of COVID-19 vaccines and how you can report side effects on the TGA website. Read more about how AusVaxSafety is conducting national COVID-19 vaccine safety surveillance in Australia here. Links to further information on the expected profile for the AstraZeneca COVID-19 vaccine are available below: Cancer Australia has developed Frequently Asked Questions (FAQs) about the COVID-19 vaccines for people affected by cancer, including dedicated FAQs for Aboriginal and Torres Strait Islander people, and translations into the ten most commonly spoken languages in Australia other than English Australian Technical Advisory Group on Immunisation (ATAGI) clinical guidance on use of COVID-19 vaccine in Australia in 2021 Patient information sheet on AstraZeneca COVID-19 vaccine and thrombosis with thrombocytopenia syndrome (TTS) COVID-19 AstraZeneca vaccine phase III trial publication Global Advisory Committee on Vaccine Safety statement on COVID-19 AstraZeneca vaccine and influenza-like illness Comparison of Comirnaty and COVID-19 AstraZeneca vaccines in United Kingdom publication AusVaxSafety will continue to closely monitor the safety data of COVID-19 vaccines in use in Australia in conjunction with the TGA. Blood cancer The profile of reported events from AusVaxSafety surveillance of the AstraZeneca COVID-19 vaccine is similar to that reported in clinical trials and from post-marketing surveillance overseas. There have been no reports of thrombosis thrombocytopenia syndrome (TTS) following COVID-19 vaccination reported to AusVaxSafety. For more information on all vaccine safety monitoring in Australia and on TTS, see weekly TGA safety updates. AusVaxSafety's active vaccine safety surveillance system complements the TGA's enhanced safety surveillance activities. Find out more about how the TGA monitors the safety of COVID-19 vaccines and how you can report side effects on the TGA website. Read more about how AusVaxSafety is conducting national COVID-19 vaccine safety surveillance in Australia here. Links to further information on the expected profile for the AstraZeneca COVID-19 vaccine are available below: Cancer Australia has developed Frequently Asked Questions (FAQs) about the COVID-19 vaccines for people affected by cancer, including dedicated FAQs for Aboriginal and Torres Strait Islander people, and translations into the ten most commonly spoken languages in Australia other than English Australian Technical Advisory Group on Immunisation (ATAGI) clinical guidance on use of COVID-19 vaccine in Australia in 2021 Patient information sheet on AstraZeneca COVID-19 vaccine and thrombosis with thrombocytopenia syndrome (TTS) COVID-19 AstraZeneca vaccine phase III trial publication Global Advisory Committee on Vaccine Safety statement on COVID-19 AstraZeneca vaccine and influenza-like illness Comparison of Comirnaty and COVID-19 AstraZeneca vaccines in United Kingdom publication AusVaxSafety will continue to closely monitor the safety data of COVID-19 vaccines in use in Australia in conjunction with the TGA. Organ transplant or bone marrow transplant recipient The profile of reported events from AusVaxSafety surveillance of the AstraZeneca COVID-19 vaccine is similar to that reported in clinical trials and from post-marketing surveillance overseas. There have been no reports of thrombosis thrombocytopenia syndrome (TTS) following COVID-19 vaccination reported to AusVaxSafety. For more information on all vaccine safety monitoring in Australia and on TTS, see weekly TGA safety updates. AusVaxSafety's active vaccine safety surveillance system complements the TGA's enhanced safety surveillance activities. Find out more about how the TGA monitors the safety of COVID-19 vaccines and how you can report side effects on the TGA website. Read more about how AusVaxSafety is conducting national COVID-19 vaccine safety surveillance in Australia here. Links to further information on the expected profile for the AstraZeneca COVID-19 vaccine are available below: Cancer Australia has developed Frequently Asked Questions (FAQs) about the COVID-19 vaccines for people affected by cancer, including dedicated FAQs for Aboriginal and Torres Strait Islander people, and translations into the ten most commonly spoken languages in Australia other than English Australian Technical Advisory Group on Immunisation (ATAGI) clinical guidance on use of COVID-19 vaccine in Australia in 2021 Patient information sheet on AstraZeneca COVID-19 vaccine and thrombosis with thrombocytopenia syndrome (TTS) COVID-19 AstraZeneca vaccine phase III trial publication Global Advisory Committee on Vaccine Safety statement on COVID-19 AstraZeneca vaccine and influenza-like illness Comparison of Comirnaty and COVID-19 AstraZeneca vaccines in United Kingdom publication AusVaxSafety will continue to closely monitor the safety data of COVID-19 vaccines in use in Australia in conjunction with the TGA. News & events All news & events 28 March 2024 | News AusVaxSafety commences routine surveillance of 2024 seasonal influenza vaccines 08 March 2024 | News Vaccine safety in Australia AusVaxSafety summary report now available 20 February 2024 | News What to expect in the days after your XBB.1.5 COVID-19 vaccine 20 December 2023 | News Shingrix® vaccine safety data now available